Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.

por Lønning, P. E.
Publicado 1998

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum

por Lønning, P. E.
Publicado 2011

Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.

por Johannessen, D. C., Adlercreutz, H., Fotsis, T., Lønning, P. E.
Publicado 1993

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.

por Lønning, P. E., Jacobs, S., Jones, A., Haynes, B., Powles, T., Dowsett, M.
Publicado 1991

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.

por MacNeill, F. A., Jacobs, S., Lønning, P. E., Powles, T. J., Dowsett, M.
Publicado 1994

Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer

por Helle, S I, Geisler, S, Aas, T, Paulsen, T, Holly, J M P, Lønning, P E
Publicado 2001

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.

por Lien, E. A., Wester, K., Lønning, P. E., Solheim, E., Ueland, P. M.
Publicado 1991

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.

por MacNeill, F. A., Jones, A. L., Jacobs, S., Lønning, P. E., Powles, T. J., Dowsett, M.
Publicado 1992

Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer

por Helle, S I, Geisler, J, Anker, G B, Leirvaag, B, Holly, J M P, Lønning, P E
Publicado 2001

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer...

por Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P. O., Lønning, P. E.
Publicado 1996

Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer

por Akslen, L A, Straume, O, Geisler, S, Sørlie, T, Chi, J-T, Aas, T, Børresen-Dale, A-L, Lønning, P E
Publicado 2011

Screening breast cancer patients for Norwegian ATM mutations

por Laake, K, Vu, P, Andersen, T I, Erikstein, B, Kåresen, R, Lønning, P E, Skovlund, E, Børresen-Dale, A L
Publicado 2000

Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.

por Ellis, P. A., Lonning, P. E., Borresen-Dale, A., Aas, T., Geisler, S., Akslen, L. A., Salter, I., Smith, I. E., Dowsett, M.
Publicado 1997

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients...

por Dowsett, M., MacNeill, F., Mehta, A., Newton, C., Haynes, B., Jones, A., Jarman, M., Lonning, P., Powles, T. J., Coombes, R. C.
Publicado 1991

Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.

por Helle, S. I., Geisler, J., Poulsen, J. P., Hestdal, K., Meadows, K., Collins, W., Tveit, K. M., Holly, J. M., Lønning, P. E.
Publicado 1998

Patterns of genomic evolution in advanced melanoma

por Birkeland, E., Zhang, S., Poduval, D., Geisler, J., Nakken, S., Vodak, D., Meza-Zepeda, L. A., Hovig, E., Myklebost, O., Knappskog, S., Lønning, P. E.
Publicado 2018

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors

por Flågeng, M Hauglid, Haugan Moi, L L, Dixon, J M, Geisler, J, Lien, E A, Miller, W R, Lønning, P E, Mellgren, G
Publicado 2009

Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES

por Cheang, M. C. U., Bliss, J. M., Viale, G., Speirs, V., Palmieri, C., Shaaban, A., Lønning, P. E., Morden, J., Porta, N., Jassem, J., van De Velde, C. J., Rasmussen, B. B., Verhoeven, D., Bartlett, J. M. S., Coombes, R. C.
Publicado 2017